Table of Contents
Chapter 1. Executive Summary
1.1. Pharmacovigilance– Industry Summary and Critical Success Factors (CSFs)
Chapter 2. Pharmacovigilance Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Pharmacovigilance – Market dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Pharmacovigilance – PESTEL Analysis
2.6. Pharmacovigilance Company Market Share Analysis, 2013
Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook
3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020
3.2. Preclinical
3.2.1. Preclinical Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.3. Phase 0
3.3.1. Phase 0 Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.4. Phase I
3.4.1. Phase I Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.5. Phase II
3.5.1. Phase II Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.6. Phase III
3.6.1. Phase III Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.7. Phase IV
3.7.1. Phase IV Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 4. Pharmacovigilance Type of Service Provider Outlook
4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020
4.2. In- House
4.2.1. In-House Market Estimates and Forecasts, 2012 – 2020 (USD Million)
4.3. Contract Outsourcing
4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 5. Pharmacovigilance Regional Outlook
5.1. Pharmacovigilance market share by region, 2012 & 2020
5.2. North America
5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.2.2. Market Estimates and Forecasts, by Type of Service Provider
5.3. Europe
5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.3.2. Market Estimates and Forecasts, by Type of Service Provider
5.4. Asia Pacific
5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.4.2. Market Estimates and Forecasts, by Type of Service Provider
5.5. RoW
5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.5.2. Market Estimates and Forecasts, by Type of Service Provider
Chapter 6. Competitive Landscape
6.1 Accenture Plc.
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Boehringer Ingelheim GmbH
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 Clinquest Group B.V.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Cognizant Technology Solutions Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Covance, Inc.
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 F. Hoffmann-La Roche Ltd
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strategic Initiatives
6.8 GlaxoSmithKline (GSK)
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 IBM Corporation
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON, Plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 iGATE Corporation
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 iMEDGlobal Corporation
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 Infosys
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Ipca Laboratories Ltd
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.14.4 Strategic Initiatives
6.15 Janssen Research & Development, LLC
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 Novartis International AG
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 PAREXEL International Corporation
6.17.1 Company Overview
6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
6.18 Pfizer, Inc.
6.18.1 Company Overview
6.18.2 Financial Performance
6.18.3 Product Benchmarking
6.18.4 Strategic Initiatives
6.19 Pharmaceutical Product Development, Inc. (PPD, Inc.)
6.19.1 Company Overview
6.19.2 Financial Performance
6.19.3 Product Benchmarking
6.19.4 Strategic Initiatives
6.20 Sanofi Aventis
6.20.1 Company Overview
6.20.2 Financial Performance
6.20.3 Product Benchmarking
6.20.4 Strategic Initiatives
6.21 Synowlwedge LLC
6.21.1 Company Overview
6.21.2 Financial Performance
6.21.3 Product Benchmarking
6.21.4 Strategic Initiatives
6.22 Wipro Ltd.
6.22.1 Company Overview
6.22.2 Financial Performance
6.22.3 Product Benchmarking
6.22.4 Strategic Initiatives
6.23 PRA Health Sciences Inc.
6.23.1 Company Overview
6.23.2 Financial Performance
6.23.3 Product Benchmarking
6.23.4 Strategic Initiatives
6.24 Quantum Solutions India
6.24.1 Company Overview
6.24.2 Financial Performance
6.24.3 Product Benchmarking
6.24.4 Strategic Initiatives
6.25 Quintiles Transnational Corporation
6.25.1 Company Overview
6.25.2 Financial Performance
6.25.3 Product Benchmarking
6.25.4 Strategic Initiatives
6.26 inVentiv Health Inc.
6.26.1 Company Overview
6.26.2 Financial Performance
6.26.3 Product Benchmarking
6.26.4 Strategic Initiatives
6.27 OptumInsight, Inc.
6.27.1 Company Overview
6.27.2 Financial Performance
6.27.3 Product Benchmarking
6.27.4 Strategic Initiatives
6.28 United BioSource Corporation
6.28.1 Company Overview
6.28.2 Financial Performance
6.28.3 Product Benchmarking
6.28.4 Strategic Initiatives
6.29 Ecron Acunova
6.29.1 Company Overview
6.29.2 Financial Performance
6.29.3 Product Benchmarking
6.29.4 Strategic Initiatives
6.30 Fortitude Clinical
6.30.1 Company Overview
6.30.2 Financial Performance
6.30.3 Product Benchmarking
6.30.4 Strategic Initiatives
6.31 ITClinical
6.31.1 Company Overview
6.31.2 Financial Performance
6.31.3 Product Benchmarking
6.31.4 Strategic Initiatives
Chapter 7. Methodology and Scope
7.1. Research Methodology
7.2. Research Scope & Assumption
7.3. List of Data Sources
List of Tables
1. Pharmacovigilance Market – Industry Summary & Critical Success Factors (CSFs)
2. Global Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020, Revenue (USD Million)
3. Global Pharmacovigilance Market Revenue, By Type of Service Provider , 2012 – 2020, Revenue (USD Million)
4. Global Pharmacovigilance Market Revenue, By Region, 2012 – 2020, Revenue (USD Million)
5. Pharmacovigilance Market – Key market driver analysis
6. Pharmacovigilance – Key market restraint analysis
7. North America Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
8. North America Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
9. North America Pharmacovigilance Market Revenue, By Type of Service provider, 2012 – 2020 (USD Million)
10. Europe Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
11. Europe Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
12. Europe Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
13. Asia Pacific Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
14. Asia Pacific Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
15. Asia Pacific Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
16. RoW Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
17. RoW Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
18. RoW Pharmacovigilance Market Revenue, By Type of Service Provider, 2012 – 2020 (USD Million)
List of Figures
1. Pharmacovigilance: Market Segmentation
2. Global Pharmacovigilance Market, 2012 – 2020, Revenue (USD Million)
3. Pharmacovigilance Market Dynamics
4. Key Opportunities Prioritized
5. Pharmacovigilance Market – Porter’s Analysis
6. Pharmacovigilance Market – PESTEL Analysis
7. Pharmacovigilance Company Market Share Analysis, 2013
8. Pharmacovigilance Market Share, By Clinical Trial Phase, 2013 & 2020
9. Pharmacovigilance Market Share, By Type of Service Provider, 2013 & 2020
10. Pharmacovigilance Market Share, By Region, 2013 & 2020